- Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome2003 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Direct factor Xa inhibitor rivaroxaban2009 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate((R)): Final report from a prospective study2018 | Second Faculty of Medicine
- Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes2005 | Central Library of Charles University, Faculty of Medicine in Pilsen
- Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes2005 | Publication without faculty affiliation
- Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project2014 | Faculty of Medicine in Pilsen
- Investigation of factor VIII inhibitor in patients with haemophilia A during interferon-alpha therapyPublication without faculty affiliation
- Determination of concentrations of tissue factor pathway inhibitor and their changes during estrogen replacement therapy2007 | First Faculty of Medicine
- Anticoagulation 20132013 | Faculty of Medicine in Hradec Králové
- Combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma2014 | First Faculty of Medicine
- Dissecting cellulitis of the scalp treated with tumour necrosis factor-α inhibitors: experience with two agents2016 | Faculty of Medicine in Pilsen
- Tumor necrosis factor alpha inhibitors or interleukin 17 inhibitors in the treatment of patients with axial spondyloarthritis2019 | First Faculty of Medicine
- Increased platelet residual activity in patients treated with acetosalicylic acid is associated with increased tissue factor and decreased tissue factor pathway inhibitor plasma levels2011 | Faculty of Medicine in Hradec Králové
- Rivaroxaban - a newly marketed antithrombotic agent2009 | First Faculty of Medicine
- Will we change the strategy of anticoagulation therapy?2022 | Third Faculty of Medicine
- The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumor necrosis factor alpha inhibitors2014 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 20032015 | Second Faculty of Medicine
- Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: Cross-over designed study2006 | First Faculty of Medicine
- Tissue factor, tissue factor pathway inhibitor, and soluble P-selectin levels in patients with acute coronary syndromes. A preliminary report.2002 | Central Library of Charles University, Second Faculty of Medicine
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study +12008 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Second Faculty of Medicine
- Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin2014 | Publication without faculty affiliation
- Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study2011 | Second Faculty of Medicine
- Acquired haemophilia A a rare complication of primary Sjögren's syndrome. Case reports and a literature review2018 | Central Library of Charles University
- Apixabans2011 | First Faculty of Medicine, Third Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | First Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | Faculty of Physical Education and Sport
- Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients2020 | Faculty of Medicine in Hradec Králové